Generic Name: elotuzumab
Drug Class: Targeted Therapy Medications
Company: Bristol-Myers Squibb
Approval Status: Approved
Generic Version Available: No
Empliciti is a SLAMF7 inhibtor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).
Empliciti is a monoclonal antibody that binds to the SLAMF7 receptor on myeloma cells. This helps immune cells known as natural killer cells recognize and attack the cancer.
Clinical trials showed that Empliciti slows progression of multiple myeloma.
Empliciti is administered as an intravenous infusion every week for the first two cycles, then every two weeks until disease progression occurs.
Common side effects include fatigue, diarrhea, fever, constipation, cough, peripheral neuropathy, decreased appetite and upper respiratory tract infections. It can cause birth defects and should not be used during pregnancy.
For More Info: https://www.empliciti.com/
Co-Pay Program Info: http://www.bmsaccesssupport.bmscustomerconnect.com/patient
Patient Assistance Program Info: http://www.bmsaccesssupport.bmscustomerconnect.com/patient
Last Reviewed: September 18, 2018